

Computational hunting of natural active compounds as an alternative for Remdesivir to target RNA-dependent polymerase

Mohd Saeed^{1*}, Amir Saeed^{2,3}, Md Jahoor Alam¹, Mousa Alreshidi¹

¹Department of Biology, college of Sciences, University of Ha'il, Hail, Saudi Arabia

²Department of Clinical Laboratory Sciences, College of Sciences, University of Ha'il, Hail, Saudi Arabia

³Department of Medical Microbiology Faculty of Medical Laboratory Sciences, University of Medical Sciences & Technology, Khartoum, Sudan

*Correspondence to: mo.saeed@uoh.edu.sa, saeedmicrobiology@gmail.com

Received September 14, 2020; Accepted December 6, 2020; Published January 31, 2021

Doi: <http://dx.doi.org/10.14715/cmb/2021.67.1.7>

Copyright: © 2021 by the C.M.B. Association. All rights reserved.

Abstract: The hunt for potential lead/drug molecules from different resources, especially from natural resources, for possible treatment of COVID-19 is ongoing. Several compounds have already been identified, but only a few are good enough to show potential against the virus. Among the identified druggable target proteins of SARS-CoV-2, this study focuses on non-structural RNA-dependent RNA polymerase protein (RdRp), a well-known enzyme for both viral genome replication and viral mRNA synthesis, and is therefore considered to be the primary target. In this study, the virtual screening followed by an in-depth docking study of the Compounds Library found that natural compound Cyclocurcumin and Silybin B have strong interaction with RdRp and much better than the remdesivir with free binding energy and inhibition constant value as -6.29 kcal/mol and 58.39 μ M, and -7.93 kcal/mol and 45.3 μ M, respectively. The finding indicated that the selected hits (Cyclocurcumin and Silybin B) could act as non-nucleotide anti-polymerase agents, and can be further optimized as a potential inhibitor of RdRp by benchwork experiments.

Key words: Virtual screening; Remdesivir, COVID-19; Cyclocurcumin.

Introduction

The threat of the COVID-19 (2019 novel coronavirus disease) is expeditiously increasing and leading to cause a global health and economic issue, causing more than 26 million cases leading to ~873,000 deaths all-inclusive, with a probable mortality rate of ~3.3 % (1). The first patient detected to have fallen from infection caused by COVID-19 was on December 01, 2019 (2-4). On March 11, 2020, the World Health Organization announced COVID-19 as a worldwide pandemic because of the rapid SARS-CoV-2 propagation globally. Now there are no effective pharmacological therapies that can evoke viral confinement and removing SARS-CoV-2 infections effectively and easily, as well as no large-spectrum medications for other pathogenic coronaviruses, except the analog nucleotide remdesivir. Several other potential drugs are currently being considered as an alternative that involves antiviral drugs (e.g. immunoglobulin, favipiravir, azvudine, and danoprevir), antimalarial drugs (hydroxychloroquine), antibiotics and antiparasitics (e.g. carrimycin, and ivermectin), kinase inhibitors, monoclonal antibodies, hormonal preparations, cardiovascular drugs and vitamins (5, 6). Even to date there is no approved vaccine against this virus, although there are many in various phases of the clinical trial. A total of 182 vaccine candidates for which 122 are in pre-clinical and 58 are in human trials (<https://www.who.int/>). Various platforms exist for the design of candidate vaccines for COVID-19 which includes nucleic acid vaccines, non-replicating viral vectors vaccines,

virus vaccines, and protein-based vaccines (7).

The sequenced whole-genome of causative pathogen (SARS-CoV-2) determined that it is closely associated with severe acute respiratory syndrome coronavirus (SARS-CoV) and is the 5th strain of beta coronaviruses (8, 9). The prevalence of contact-to-contact transmission of coronavirus is probably due to the high virus spike protein interaction with the host receptor (10-12), leading to a rapid increase of infection globally.

The viral RNA synthesis is catalyzed by the RNA-dependent RNA polymerase (RdRp, also named as nsp12), a vital element of coronavirus replication or transcription machinery, and therefore consider as the important therapeutic target for antiviral drugs (13). RdRp has minimal activity alone (14), but its polymerase activity is greatly enhanced by the association of nsp7 and nsp8 cofactors. NSP7 and NSP8 maximize RdRp binding and assassination as accessory factors. Like other polymerases, RdRp has a polymerase domain whose structure resembles a cupped "right hand". A fingers domain, a palm domain, and a thumb domain are also present in the polymerase domain (15, 16). RdRp is important for viral genome replication as well as viral mRNA synthesis (13, 17). RdRp is therefore regarded as the main target for analog antiviral nucleotide inhibitors i.e. remdesivir which have an active drug within the cells and display a possible application of COVID-19 therapy.

Remdesivir was originally established for the control of Ebola and Marburg viruses. Studies have shown that remdesivir lowers viral titers and viral RNA in both

Table 2. ADME properties of top screened compounds Silybin B and Cyclocurcumin.

ID	Value	
	Silybin B	Cyclocurcumin
BBB	0.0608989	0.09951
Buffer_solubility_mg_L	9.00919	344.138
Caco2	4.84461	26.8009
CYP_2C19_inhibition	Inhibitor	Inhibitor
CYP_2C9_inhibition	Inhibitor	Inhibitor
CYP_2D6_inhibition	Non	Non
CYP_2D6_substrate	Non	Non
CYP_3A4_inhibition	Inhibitor	Inhibitor
CYP_3A4_substrate	Weakly	Weakly
HIA	78.550647	94.138899
MDCK	0.0556942	0.125313
Pgp_inhibition	Non	Inhibitor
Plasma_Protein_Binding	87.754608	90.515082
Pure_water_solubility_mg_L	1.09166	11.4956
Skin_Permeability	-4.23602	-2.9169
SKlogD_value	2.37608	3.5204
SKlogP_value	2.37608	3.5204
SKlogS_buffer	-4.72876	-3.02957
SKlogS_pure	-5.64536	-4.50577

was 58.39 μM , and 37.35 μM , respectively (Table 1). Amino acid residues Gly590, Thr591, and Leu758 of RdRp were found to make hydrogen bond with Silybin B (Figure 2A); while Asp760 and Cys813 are the common hydrophobic interacting amino acid residues of RdRp with Cyclocurcumin and Silybin B (Figure 2B). The identified compounds (Cyclocurcumin and Silybin B) exhibited promising ADMET properties, none of which were found to contain any high-risk chemical group (Table 2). Figure 3 indicates the surfaces of the receptors, such as interpolated charge, H-bond, hydrophilicity and solvent-accessible surface (SAS). The hydrophobicity surface suggested that the receptor inside the molecule has more hydrophilic properties. SAS is the surface area of a protein that can be covered by a solvent. Here, in both receptor ligand complexes, the SAS surface revealed that 7BV2 residues had a relatively high SAS propensity.

Discussion

Phytochemicals contain a range of molecules with various curative potentials and have been recognized as a significant resource for the development of new drug therapies (18). Natural product-derived phytochemicals can be used to create more active drugs based on natural compound structures (19, 20). RdRp is a conserved enzyme that is essential for the replication and transcription of coronavirus genomes (15, 21).

The degree of interaction between ligand and protein is determined by binding energy and the high (negative) energy implies the successful binding of the inhibitor with its target protein (22, 23). Consequently, the detachment rate of such a ligand with its target protein is lower and this ligand may have an increased half-life (24). Accordingly, Cyclocurcumin and Silybin B have successful binding to RdRp compared to other compounds




Figure 2. Ligplot analysis of RdRp showing the hydrophobic interacting amino acid residues (red arcs) and hydrogen bond (green dashed line) with A) Silybin B, and B) Cyclocurcumin.

and are much stronger than the remdesivir in terms of binding capacity in this study (Table 1). Remdesivir is the only authorized treatment for the person suffering from serious COVID-19 infection (25). Curcumin derivatives such as dihydrocurcumin glucuronide and curcumin sulfate have shown effective RdRp binding in a recent study (26). Computational experiments targeting RdRp's active site investigated many natural compounds including hesperidin, glycyrrhizin, quercetagenin, myricetin to be an effective inhibitor (27, 28).

Ligplot/2D interaction analysis shows that Cyclocurcumin and Silybin B make hydrogen and hydrophobic interaction with the important amino acid residue of RdRp. It has been revealed that both hydrogen and hydrophobic interaction are vital in the stability of inhibitors to its corresponding protein (29, 30).

The RdRp active site comprises of seven conserved motifs (A to G). Motifs A, B, C, and D are from the palm subdomain, with the amino residues Ser759, Asp760, and Asp761 in motif C form the active site center (31).




Figure 3. The schematic representation of interpolated charge, H-bond, hydrophobicity, and SAS of 7BV2 around Silybin B, and Cyclocurcumin.

Interestingly, RdRp's amino residue Ser759, Asp760, and Asp761 have been shown to interact with Silybin B in this study. Besides, Cyclocurcumin has also been found to bind with amino residue Asp760 of RdRp. The result indicated that the selected hits (Cyclocurcumin and Silybin B) could act as non-nucleotide anti-polymerase agents. The uniqueness of this study is that these natural compounds can be further tested for antiviral efficacy, as our computation study indicates that these compounds have a better binding efficacy to the RdRp active site than remdesivir and are naturally less toxic.

Various techniques (*in silico*, *in vitro*, and *in vivo*) are being used to find out the cure for the COVID-19 global pandemic. In this research, *in silico* screening technique was used to identify a possible anti-viral agent for a novel infection with COVID-19. Compounds obtained from virtual screening were subjected to molecular docking experiments to assess their interactive stability at the RdRp catalytic site and finally was found that Cyclocurcumin and Silybin B efficiently bind with RdRp and can be further studied (*in vitro* and *in vivo* assessments) for their optimization as a potential inhibitor of RdRp.

Acknowledgments

The authors extend their appreciation to the King Abdulaziz City for Science and Technology (KACST) for funding this work through the project No. 5-20-01-021-0005.

Conflict of Interest

The authors declare no conflict of interest.

References

1. WHO. Coronavirus Disease 2019 (COVID-19): Situation Report-134, 2020.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. *Lancet*. 2020;395:497–506.
3. Balaramnavar VM, Ahmad K, Saeed M, Ahmad I, Kamal M, Jawed T. Pharmacophore-based approaches in the rational repurposing technique for FDA approved drugs targeting SARS-CoV-2 M pro. *RSC Advances*. 2020;10(66):40264-75.

4. SSaeed M, Saeed A, Alam MJ, Alreshidi M. Identification of Persuasive Antiviral Natural Compounds for COVID-19 by Targeting Endoribonuclease NSP15: A Structural-Bioinformatics Approach. *Molecules*. 2020 Dec 1;25(23):5657-5. Sarkar C, Mondal M, Torequl Islam M, Martorell M, Docea AO, Maroyi A, Sharifi-Rad J and Calina D. Potential therapeutic options for COVID-19: current status, challenges, and future perspectives. *Frontiers in Pharmacology*. 2020;11:572870.
6. Torequl Islam M, Nasiruddin M, Khan IN, Mishra SK, Kudrat-E-Zahan M, Alam Riaz T, Ali ES, Rahman MS, Mubarak MS, Martorell M, Cho WC, Calina D, Docea AO and Sharifi-Rad J. A perspective on emerging therapeutic interventions for COVID-19. *Frontiers in Public Health*. 2020;8:281.
7. Calina D, Sarkar C, Arsene AL, Salehi B, Docea AO, Mondal M, Torequl Islam M, Zali A, Sharifi-Rad J. Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. *Immunologic Research*. 2020;68:315–324.
8. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) *in vitro*. *Cell Research*. 2020;30(3):269–271.
9. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. *Current Biology*. 2020;30:1346-1351.
10. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science*. 2020;367(6485):1444-1448.
11. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. *Nature*. 2020;581:215–220.
12. Shang J, Ye G, Shi K, Wan Y, Luo C, Aiharaet H, et al. Structural basis of receptor recognition by SARS-CoV-2. *Nature*. 2020;581:221–224.
13. Gao Y, Yan L, Huang Y, Liu F, Zhao Y, Cao L, Wang T, et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science*. 2020;368(6492):779–782.
14. Zhang L, Lin D, Sun X, Curth U, Drosten C, Sauerhering L, Becker S, Rox K, Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α -ketoamide inhibitors. *Science*. 2020;368(6489):409-412.
15. Chen YW, Yiu CPB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candi-

- dates. *F1000Research*. 2020;9:129.
16. Khan SA, Zia K, Ashraf S, Uddin R, Ul-Haq Z. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach. *Journal of Biomolecular Structure Dynamics*. 2020;13:1-10.
17. Romano M, Ruggiero A, Squeglia F, Maga G, Berisio R. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping. *Cells*. 2020. 9:1267; doi:10.3390/cells9051267.
18. Sharifi-Rad J, Kamiloglu S, Yeskaliyeva B, Beyatli A, Alfred MA, Salehi B, Calina D, Docea AO, Imran M, Anil Kumar NV, Romero-Román ME, Maroyi A and Martorell M. Pharmacological activities of Psoralidin: a comprehensive review of the molecular mechanisms of action. *Frontiers Pharmacology*. 2020;11:571459.
19. Salehi B, Sharifi-Rad J, Cappellini F, Reiner Z, Zorzan D, Imran M, Sener B, Kilic M, El-Shazly M, Fahmy NM, Al-Sayed E, Martorell M, Tonelli C, Petroni K, Docea AO, Calina D and Maroyi A. The Therapeutic Potential of Anthocyanins: Current Approaches Based on Their Molecular Mechanism of Action. *Frontiers in Pharmacology*. 2020;11:1300.
20. Mani JS, Johnson JB, Steel JC, Broszczak DA, Neilsen PM, Walsh KB, Naiker M. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. *Virus Research*. 2020;284:197989.
21. Lung J, Lin YS, Yang YH, Chou YL, Shu LH, Cheng YC, Liu HT, Wu CY. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. *Journal of Medical Virology*. 2020;92(6):693–697.
22. Verma A, Rizvi SMD, Shaikh S, Ansari MA, Shakil S, Ghazal F, et al. Compounds isolated from *Ageratum houstonianum* inhibit the activity of matrix metalloproteinases (MMP-2 and MMP-9): An oncoinformatics study. *Pharmacognosy Magazine*. 2014;10:18–26.
23. Rizvi SMD, Shakil S, Zeeshan M, Khan MS, et al. An enzoinformatics study targeting polo-like kinases-1 enzyme: Comparative assessment of anticancer potential of compounds isolated from leaves of *Ageratum houstonianum*. *Pharmacognosy Magazine*. 2014;10:14–21.
24. Copeland RA. Conformational adaptation in drug–target interactions and residence time. *Future Medicinal Chemistry*. 2011;3(12):1491-1501.
25. FDA. 12 April 2020. Coronavirus (COVID-19) update: FDA issues emergency use authorization to decontaminate millions of N95 respirators.
26. Bastikar VA, Bastikar AV, Chhajed SS. Understanding the role of natural medicinal compounds such as curcumin and allicin against SARS-CoV-2 proteins as potential treatment against COVID-19: An in silico approach. *Journal of Proteomics & Bioinformatics*. 2020;13:7.
27. Singh, S., Sk, M. F., Sonawane, A., Kar, P., & Sadhukhan, S. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: An in-silico analysis. *Journal of Biomolecular Structure and Dynamics*, 2020; 1-16.
28. Verma, S., Twilley, D., Esmear, T., Oosthuizen, C. B., Reid, A. M., Nel, M., & Lall, N. Anti-SARS-CoV natural products with the potential to inhibit SARS-CoV-2 (COVID-19). *Frontiers in Pharmacology*, 2010; 11, 1514.
29. Shaikh S, Rizvi SMD, Hameed N, Biswas D, Khan M, Shakil S, Kamal MA. Aptiom (Eslincarbazepine acetate) as a dual inhibitor of β -secretase and Voltage-gated sodium channel: advancement in Alzheimer's disease-Epilepsy linkage via an enzoinformatics study. *CNS & Neurological Disorders - Drug Targets* 2014;13(7):1258-1262.
30. Shaikh S, Rizvi SM, Suhail T, Shakil S, Abuzenadah AM, Anis R, Naaz D, Haneef M, Ahmad A, Choudhary L. Prediction of anti-diabetic drugs as dual inhibitors against acetylcholinesterase and beta-secretase: a neuroinformatics study. *CNS Neurol Disord - Drug Targets* 2016;15(10):1216-1221.
31. Yin W, Mao C, Luan X, et al. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by Remdesivir. *Science*. 2020;368:1499–1504.